A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(13 sites)

United States

University of Alabama at Birmingham, Birmingham, Alabama

Children's Hospital Los Angeles, Los Angeles, California

Children's Hospital Colorado, Aurora, Colorado

Children's National Hospital, Washington D.C., District of Columbia

Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois

University of Chicago, Chicago, Illinois

Indiana University, Indianapolis, Indiana

Johns Hopkins Hospital, Baltimore, Maryland

Washington University School of Medicine, St Louis, Missouri

New York University Langone Health, New York, New York

Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio

Children's Hospital of Philadelphia, Philadelphia, Pennsylvania

University of Texas Southwestern Medical Center, Dallas, Texas